Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. The M&A streak continues. Read on for the news today.

Novo to buy MASH drugmaker Akero Therapeutics

Novo Nordisk said this morning that it will buy Akero Therapeutics, the developer of a drug to treat the liver disease known as MASH, for up to $5.2 billion.

To read the rest of this story subscribe to STAT+. Subscribe Log In

See Full Page